With $19 million of Series A venture capital in its pocket as of last week, and a former Perkin-Elmer executive at its head, separations start-up Protein Forest is hoping to replace the use of 2D gels in pharma’s and biotech’s proteomics core laboratories with its miniaturized ProteomeChip, set for launch in Q4 2004. The Watertown, Mass.-based company closed the $19 million series last week, with four firms — S.R. One, Boston Millennia Partners, IDG Ventures, and Novo A/S — leading the charge.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.